First Therapy Approved for Marinus and Seizures Associated with CDD

Marinus Pharmaceutical's proposed oral drug for seizures has received approval from the U.S. Food and Drug Administration, with projected market availability of July 2022. It was the first sole drug approval for the Radnor, Pennsylvania-based company.